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Abstract
Background: The acute and chronic leukaemias constitute about 2.5% of all newly diagnosed
malignancies and kill over 4000 people/year in the UK, yet there is little accurate up-to-date data
on how the incidence of and mortality from leukaemias vary with socio-economic status in the UK.
We aimed to quantify the incidence of and mortality from leukaemias in the UK and their variation
with gender, age, year of diagnosis as well as socio-economic status.
Methods: All incident cases of leukaemia were identified in 'The Health Improvement Network'
(THIN) General Practice dataset. Crude incidence rates and incidence rate ratios (using Poisson
Regression) stratified by age, gender, year of diagnosis and socio-economic status were calculated.
Median survival and hazard ratios for risk of death (using Cox regression) were then calculated, and
stratified in a similar manner.
Results: A total of 4162 cases of leukaemia were identified, 2314 (56%) of whom were male. The
overall incidence of leukaemia was 11.25 per 100 000 person-years. The age and gender
distributions of ALL, AML, CLL and CML were similar to UK cancer registry data. The incidence
of leukaemias was independent of socio-economic class. Median survival from leukaemia was 6.58
years and mortality increased with increasing age at diagnosis. The prognosis in AML was dismal
and worsened with increasing socio-economic deprivation. For other leukaemias mortality was
independent of socio-economic status.
Conclusion: This is the first general population study to describe the incidence of and mortality
from leukaemias in the UK by socio-economic status. Similar mortality across socio-economic
gradients in the leukaemias studied suggests equal access to and uptake of services. The exception
to this was in AML, where poorer survival in AML patients from lower socio-economic classes may
represent a class bias in treatment offered and/or greater co-morbidity in these patients, and
warrants further exploration.
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Background
The acute and chronic leukaemias constitute 2.5% of all
cancers and together are the 12th most common cancer
registered in the UK [1]. Approximately 7000 people are
diagnosed with these diseases and more than 4300 people
die from leukaemias in the UK each year [1]. Although the
Office of National Statistics, cancer charities and cancer
registries in the UK make valuable contributions to our
knowledge on its variation by gender and age, as well as
trends over time, there is a paucity of contemporary data
on disease incidence and mortality and how these vary by
socio-economic circumstances. A source of general popu-
lation derived figures that could be updated regularly
would be very helpful when planning medical services
and ensuring equal access to these services.
More than 97% of people in the UK are registered with a
general practitioner, which makes GP databases an excel-
lent general population source of data on disease inci-
dence and mortality. Diagnoses of cancer have been
examined in general practice databases before and have
been found to be valid [2]. This means that computerised
general practice data may be a valuable new resource for
leukaemia research. In addition to medical and prescribed
drug histories held in these datasets, such datasets can also
readily supply controls for studying disease aetiology,
which gives them an advantage over registry data.
As part of a programme of research on leukaemia using
general practice datasets we set out to quantify the inci-
dence of and mortality from leukaemias in the UK, and
the variation of these with gender, age, calendar time and
socio-economic status.
In this article we report the associations we found
between socio-economic class and both leukaemia inci-
dence, and mortality in the UK.
Methods
'The Health Improvement Network' (THIN) dataset is a
computerised dataset from over 330 general practices
across England, Scotland, Wales and Northern Ireland,
and includes 5.7 million patients, 2.5 million of whom
are actively contributing data and can be prospectively fol-
lowed. Data held include patient demographic data,
Townsend score of socio-economic deprivation, as well as
their medical and prescribed-drug histories. 'THIN' data
represent all sections of the general population of the UK
[3]. The total number of usable patients in the dataset was
5 395 612, with 2 592 133 actively contributing data on
1st July 2007 when data for this study were extracted. Data
from 1987 to 2006 are included in this study.
A list of diagnostic codes, called READ codes (available
on request) was used to identify all cases with an inci-
dent diagnosis of leukaemia in the dataset. Since retro-
spective diagnoses may be entered into patient records
at the time the patient first joins a general practice, or
when a general practice first starts to use diagnostic
software, cases were only included as incident cases in
the analyses if their first ever recording of a diagnosis of
leukaemia occurred at least 12 months after their gen-
eral practice records were computerised. We grouped
our leukaemia diagnoses on the basis of READ code
descriptions as follows: Acute Lymphoblastic Leukae-
mia (ALL), Chronic Lymphocytic Leukaemia (CLL),
Unspecified Lymphocytic or Lymphoid Leukaemia,
Acute Myeloid Leukaemia (AML), Chronic Myeloge-
nous Leukaemia (CML), and Unspecified Myelogenous
or Myeloid Leukaemia. The 'unspecified' groups do not
represent discrete diseases, but represent patients with
either lymphoid or myeloid leukaemia, but who we
could not further classify into acute or chronic catego-
ries. Myelodysplastic Syndromes have been excluded.
In order to calculate disease incidence we used the
entire population within the THIN dataset as our
denominator. The 'THIN' mid-year population (as at 1st
July) was stratified by gender, age and Townsend score
for this purpose.
For our analysis we grouped age at diagnosis into 5, 20-
year age categories with category 1 being those aged <20
yrs and category 5 representing those aged 80 yrs and
above. Year of diagnosis was grouped into 4, 5-year bands
with 1987–1991 being the first year-band and 2002–2006
the most recent. Townsend Score, a measure of socio-eco-
nomic deprivation, is derived from 2001 census output
data and is a multifaceted index of deprivation based on
unemployment, car ownership, home ownership and
overcrowding. Townsend Scores are divided into quin-
tiles, with higher scores representing greater socio-eco-
nomic deprivation [4]. Whilst not an individual measure
of deprivation, it represents a small homogenous socio-
geographic area of about 150 homes.
Initially we calculated crude incidence rates for leukaemia
and its subtypes, and stratified these estimates by gender,
age at diagnosis, year of diagnosis and Townsend Score.
We used Poisson regression to estimate incidence rate
ratios, both independently and mutually adjusted for gen-
der, age, year of diagnosis and Townsend Score.
We estimated median survival from leukaemia and its
subtypes, and then used Cox regression to calculate haz-
ard ratios, adjusted for gender, age-category, year of diag-
nosis and Townsend Score. All analyses were conducted
using STATAv9.
Ethical approval for the study was obtained from the Not-
tingham Research Ethics Committee.BMC Cancer 2009, 9:252 http://www.biomedcentral.com/1471-2407/9/252
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Results
Incidence
We identified a total of 4162 cases of leukaemia, 2314
(56%) of whom were male. Children aged 10 or younger
constituted 4.5% of cases, of whom 56% were male. The
overall incidence of leukaemia in the study population
was 11.25 per 100 000 person-years. We were able to
identify 3226 (78%) of the leukaemia cases as falling into
one of the 6 sub-types of interest. The crude incidence
rates are shown in Additional file 1. CLL was the most
common subtype and ALL the least common, with crude
incidence rates of 4.20 and 0.49 per hundred thousand
person years, respectively. The distribution of age at diag-
nosis of leukaemia by subtype is shown in Figure 1 (see
Figure 1). Most cases of ALL were diagnosed in early child-
hood, whilst the other forms of leukaemia were largely
diseases of adulthood that increased in incidence with
age.
Results of Poisson regression are shown in Additional file
2, in which incident rate ratios are adjusted for all other
variables in the table. Females had a lower incidence of
CLL, unspecified lymphoid leukaemia and AML. The inci-
dence of all sub-types, except ALL, increased with increas-
ing age at diagnosis (p for trend < 0.001). Interestingly the
incidence of ALL decreased with increasing socio-eco-
nomic deprivation, although this trend did not reach sta-
tistical significance (p for trend = 0.15).
Survival
The median survival from all leukaemias in this study was
6.58 years. The median survival from each subtype is
shown in Additional file 3 and the Kaplan-Meier survival
curves are plotted by subtype in Figure 2. ALL had the best
prognosis, with more than 50% of cases surviving the fol-
low-up period. For this reason we calculated the 5-year
survival for ALL and this was 69%. The poorest median
survival, of only 9 1/2 months was seen in AML.
The results of Cox regression are shown in Additional file
4. We found that women with CLL had a better prognosis
than men (HR 0.58, p < 0.001, 95%, C.I. 0.48–0.71).
These hazard ratios were adjusted for age-category,
Townsend Score and year of diagnosis. We did not find
this gender difference in the other specified leukaemia
sub-types studied. We saw a poorer prognosis with
increasing age at diagnosis in all subtypes (p for trend <
0.001). In AML the mortality increased with increasing
deprivation such that mortality rates were nearly 50%
higher in the most deprived quintile of Townsend Score
than for the least deprived quintile (p for trend = 0.03).
We did not find a socio-economic gradient in survival in
other leukaemias. Mortality has remained stable over cal-
endar time, except in CML, which showed a decreasing
trend in mortality of borderline statistical significance (p
for trend = 0.05).
Age at Diagnosis of leukaemia subtypes Figure 1
Age at Diagnosis of leukaemia subtypes.
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Discussion
The overall incidence of leukaemia in our study was 11.25
per 100, 000 person years which is very similar to the fig-
ure reported by Cancer Research UK which is 11.7 [1].
Similarly, the age and gender distribution of our cases is
very similar to those reported by Cancer Research UK [1]
and others [5]. CLL and AML were more common in men.
The incidence of ALL tended to decrease with increasing
deprivation. There has been an increase in the incidence
of ALL, CLL and AML over the past 20 years, but whether
this represents a true increase or better data recording, or
both, is not clear. Our survival figures are also as expected
[5] being dismal for AML. Men with CLL had a worse
prognosis than women. Prognosis was worse with increas-
ing age at diagnosis in all sub-types. Survival in AML wors-
ened with increasing socio-economic deprivation, a trend
not present for other leukaemias. Only the survival for
CML has improved with time. The MRC (Medical
Research Council, UK) AML trial data show a consistent
improvement in survival over time for younger, but not
older, patients [6]. The fact that our data does not show an
improvement in AML survival over time reflects the over-
all age distribution of AML, i.e. mostly older people, many
of whom are not entered into clinical trials.
The main strength of our study is that the large size of the
study population has allowed us to calculate precise up-
to-date estimates of the incidence of leukaemia in the UK,
and stratify these by age, gender and socio-economic class.
Furthermore, the extensive follow-up data contained in
this dataset have enabled us to accurately calculate mor-
tality rates. By using THIN data we have also had access to
a number of covariates by which to stratify our results. As
this was a general population based study, we have had
access to more data than would have been the case with a
centre-based study, and we have also had access to general
population controls. We have therefore been able to con-
duct a detailed study of high quality.
One potential weakness of this study is the issue of diag-
nostic validity in the dataset. In other words, do people
recorded as having leukaemia really have this condition?
It seems to us unlikely that a GP will record a diagnosis of
leukaemia unless there is good evidence from secondary
care to support this. Furthermore, the age and gender dis-
tributions of disease incidence are as expected [1], giving
validity to our findings. By having carefully excluded prev-
alent cases we can be certain that our incidence rates are
not spuriously elevated, and that any trends over time
have not been masked. The fact that our trends in mortal-
ity over time are comparable to those published elsewhere
[1] suggests that we have accurately identified incident
cases. We acknowledge that a small percentage of cases
had non-specific codes and we were therefore unable to
classify them into more specific sub-types.
The overall incidence we found is consistent with the
crude incidence rate of 11.7 per 100, 000 population pub-
Kaplan-Meier survival curves for each leukaemia subtype Figure 2
Kaplan-Meier survival curves for each leukaemia subtype.
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lished by Cancer Research UK for 2004 [1]. The distribu-
tion of age at diagnosis of leukaemia we have shown is
also consistent with the findings of others [1,5]. Other
studies have shown a similar incidence in ALL in men and
women, and a higher incidence in men of both CLL and
AML [7,8], in keeping with our results.
The previous studies of leukaemia and socio-economic
class have given inconsistent results. Studies prior to the
1980s mainly found higher incidences of leukaemia in
higher social classes [7,9,10], in both adults and children.
Since the 1980s, however, studies have consistently
reported inverse associations with socio-economic class
[11]. This apparent change in direction of the association
may be explained by differences in study design and/or
measures of socio-economic deprivation that have been
used over time. Most studies prior to the 1980s were eco-
logical studies whilst after this time most studies were
case-control studies and used individual-level measures of
income and education, rather than ecological-level indi-
cators of socio-economic status [11]. The more recent
studies have therefore classified the socio-economic status
of cases more accurately.
Worse survival with increased age at diagnosis is an
entirely expected finding and is in keeping with other
published data [1]. Our finding of worse survival in men
than women with CLL is also consistent with that of oth-
ers [12]. While men have a lower life-expectancy than
women overall, the difference in survival between men
and women with CLL may also represent gender differ-
ences in disease phenotype, stage of presentation and/or
response to treatment, factors which we could not eluci-
date in this dataset. Studies of the impact of socio-eco-
nomic class on mortality in leukaemia overall have shown
conflicting results [5,7,13]. The results of studies that have
investigated the association of socio-economic status and
survival in ALL specifically have also been conflicting
[11,14]. To our knowledge research into this association
in other leukaemia sub-types has not been published
more recently than that by Cartwright [7].
Conclusion
We have demonstrated that general practice data is a val-
uable resource for leukaemia research. We have been con-
ducted a contemporary population-based incidence and
mortality study stratified by age, gender and socio-eco-
nomic class, which has not been done in the UK before.
We have also shown that AML survival is dismal, and is
related to social class. Poorer survival in AML patients
from lower socio-economic classes may represent a class
bias in treatment offered and/or greater co-morbidity in
these patients, and warrants further exploration.
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